Wuhan YZY Biopharma Co Ltd (2496.HK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 12 | 2 | 12 | 108 | 65 | 73 | - |
| Operating profit | CNY m | -88 | -47 | ||||||
| Net profit | CNY m | - | -149 | -189 | -191 | -98 | -83 | -45 | - |
| EPS reported | CNY | -0.42 | -0.23 | ||||||
| Operating cashflow per share | CNY | -0.11 | -0.21 | ||||||
| Capex per share | CNY | 0.00 | 0.01 | ||||||
| FCF per share | CNY | -0.12 | -0.21 | ||||||
| Free cash flow | CNY m | -22 | -41 | ||||||
| Net debt | CNY m | 27 | 63 | ||||||
| Book value equity | CNY m | -53 | -59 | ||||||
| Book value per share | CNY | -0.27 | -0.30 | ||||||
| Number of shares | m | 193.85 | 193.85 | ||||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -26.32 | -23.85 | ||||||
| P/S LTM | x | 21.44 | 19.10 | ||||||
| P/FCF LTM | x | -62.16 | -33.90 | ||||||
| EV/EBITDA LTM | x | -17.02 | -37.84 | ||||||
| EV/Sales LTM | x | 21.87 | 6.60 | ||||||
| Earnings Yield LTM | % | -5.91% | -13.54% | ||||||
| FCF Yield | % | -1.61% | -2.95% | ||||||
| Quality | |||||||||
| ROE | % | +155.58% | +154.12% | ||||||
| ROIC | % | -1.17% | -94.94% | ||||||
| Operating margin | % | -1.35% | -79.78% | ||||||
| Gross margin | % | +9.48% | +30.78% | ||||||
| FCF/Sales | % | -34.49% | -43.23% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -39.59% | -32.19% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.18 | -0.30 | ||||||
| Net Debt/EBITDA | x | -0.33 | -0.96 | ||||||
| EBIT/Net interest | x | -18.23 | -13.78 | ||||||
| Net debt/market cap | % | +9.15% | +24.49% | ||||||
| Net debt/Equity | x | -0.52 | -1.07 | ||||||
| Gross debt/equity | x | -2.41 | -2.37 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Wuhan YZY Biopharma Co Ltd (2496.HK)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free